New drug combo aims to control advanced breast cancer
NCT ID NCT07285382
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two different doses of the drug dalpiciclib combined with letrozole in 120 women with a specific type of advanced breast cancer (HR-positive, HER2-negative). The goal is to see how long the cancer stays under control and how safe the treatment is. Participants will be randomly assigned to one of two dose levels and monitored regularly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Qingdao University Affiliated Hospital
RECRUITINGQingdao, Shandong, 266000, China
-
The Second Affiliated Hospital of Dalian Medical University
RECRUITINGDalian, Liaoning, 116027, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill combo outpace chemotherapy for aggressive breast cancer?
- Real-world data may reveal true value of abemaciclib for advanced breast cancer
- New drug combo shows promise against hard-to-treat breast cancer
- New combo aims to outperform current standard in advanced breast cancer
- New drug cocktail aims to control advanced breast cancer
- New hope for advanced breast cancer: drug combo trial opens